FCOMV
CGEM icon

Foresite Capital Opportunity Management V’s Cullinan Oncology CGEM Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-330,836
Closed -$3.46M – 10
2022
Q1 		$3.46M Sell
330,836
-50,166
-13% -$678K 4.85% 5
2021
Q4 		$5.88M Buy
+381,002
New +$7.6M 3.94% 6

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Foresite Capital Opportunity Management V's CGEM Position: Q2 2022 in Review

Foresite Capital Opportunity Management V sold out of Cullinan Oncology (CGEM) in Q2 2022, closing a stake of 330,836 shares — an estimated $3.46M sold.

Foresite Capital Opportunity Management V first reported a position in CGEM in Q4 2021 and held it in 2 quarters. The position peaked at $5.88M in Q4 2021. 89 funds tracked by Wall St. Rank hold CGEM as of Q2 2022.

  • Foresite Capital Opportunity Management V reported no remaining Cullinan Oncology position as of Q2 2022 after selling out during the quarter.
  • Foresite Capital Opportunity Management V sold 330,836 Cullinan Oncology shares in Q2 2022, an estimated $3.46M.
  • Foresite Capital Opportunity Management V first reported a position in Cullinan Oncology in Q4 2021 and held it in 2 quarters.
  • Foresite Capital Opportunity Management V's Cullinan Oncology position peaked at $5.88M in Q4 2021.
  • 89 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q2 2022, filed 12 Aug 2022.